Similarly, Zamani et al. reported a liposomal peptide-based cancer vaccine that simultaneously delivered HER2/neu-derived peptides (AE36 and E75), a multi-epitope peptide (E75-AE36), and a Pan HLA DR-binding epitope (PADRE) peptide. Here, ERBB2 is linked to cancer.